Molecular and cellular biology of heart failure

Current Opinion in Cardiology

Volumn 11, Issue 3, 1996, Pages 227-236

  Schwartz, Ketty ^a   Mercadier, Jean Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM ION; MYOSIN; PROTEIN C; TROPONIN T;

CARDIOMYOPATHY; CELL DEATH; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENOTYPE; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; SODIUM CALCIUM EXCHANGE;

APOPTOSIS; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MUSCLE FIBERS; MYOCARDIAL CONTRACTION; MYOFIBRILS; RECEPTORS, ADRENERGIC, BETA; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; TROPONIN; TROPONIN T;

EID: 0029977126     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199605000-00002     Document Type: Review

References (75)

1. Report and Recommendations of the Panel to Assess the NIH Investement in Research on Gene Therapy. Bethesda: National Institutes of Health, 1995.
2. Collins FS: Positional cloning moves from perditional to tranditional. Nature Genet 1995, 9:347-350.
3. Dib C, Fauré S, Fizames C, Samson D, Drout N, Vignal A, Millasseau P, Séboun E, Marc S, Lathrop M: A comprehensive genetic map of the human genome based on 5264 microsatillites. Nature 1996, 380:152-154. This map is one more milestone in the Human Genome Project and in the discovery of human genes. It was produced by the Généthon, with the main financial support of the Association Française contre les Myopathies (the French Muscular Dystrophy Association). The first map published by the same group in 1992 was the most cited scientific paper the year after and is an invaluable tool for gene hunters. The new map brings the genetic mapping phase of the Human Genome Project to completion.
4. Hudson TJ, Stein LD, Gerety SS, Ma J, Castle AB, Silva J, et al.: An STS- based map of the human genome. Science 1995, 270:1945-1954. Physical map of the human genome integrating 15,000 sequence tagged sites (a short, unique DNA sequence detected by polymerase chain reaction).
5. Wigle ED, Rakowski H, Kimball BP, Williams WG: Hypertrophic cardiomyopathy: clinical spectrum and treatment Circulation 1995, 92:1680-1692. Clear and updated overview in the "From Bench to Bedside" series of Circulation.
6. Vulpian A: Contribution à l'étude des rétrécissements de l'orifice ventriculo-aortique. Arch Physiol 1868, 3:456-457.
7. Schwartz K: Familial hypertrophic cardiomyopathy: nonsense versus missense mutations [editorial]. Circulation 1995, 91:2865-2867. Editorial that accompanied the paper by Nishi et al. (Circulation 1995, 91:2911-2915), in which the functional implications of nonsense versus missense mutations are discussed in general.
8. Schwartz K, Carrier L, Guicheney P, Komajda M: Molecular basis of familial cardiomyopathies. Circulation 1995, 91:532-538. Comprehensive and well-documented review that placed particular emphasis on the genetic bases of cardiomyopathies and on the correlations between the clinical manifestations and the mutant genotype. It was one of the six reviews of the special "Bugher Research Series" of Circulation that marked the 10th anniversary of the American Heart Association's Bugher Foundation program, which has given six Centers for Molecular Biology in the Cardiovascular System awards since 1985.
9. Watkins H, Seidman JG, Seidman CE: Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum Mol Genet 1995, 4:1721-1727. Review of the various disease genes of FHCM, in which the mechanism of dominant action of the mutations is clearly exposed, as well as the structure-function analyses of mutant peptides.
10. Marian AJ, Roberts R: Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995, 92:1336-1347. This review is part of the "From Bench to Bedside" series of Circulation, in which the future application of molecular genetic tools in FHCM are clearly discussed.
11. MacRae CA, Ghaisas N, Kass S, Donnely S, Basson CT, Watkins HC, Anan R, Thierfelder LH, McGarry K, Rowland E, et al.: Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995, 96:1216-1220.
12. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S, James M, Weissenbach J, et al.: Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:438-440. Identification of the disease gene of the CMH4 locus in FHCM. A mutation in a splice acceptor site of the MyBP-C gene is described in two French families. This paper was published in the same issue as that by Watkins et al. (Nat Genet 1995, 11:434-437.
13. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna W, Maron BJ, Seidman JG, Seidman CE: Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:434-437. Identification of the disease gene of the CMH4 locus in FHCM. A mutation in a splice donor site and a duplication mutation of the MyBP-C gene are described in two families. This paper was published in the same issue as that of Bonne et al. (Nat Genet 1995, 11:438-440).
14. Carrier L, Hengstenberg C, Beckmann JS, Guicheney P, Dufour C, Bercovic J, Dausse E, Berebbi-Bertrand I, Wisnewsky C, Pulvenis D, et al.: Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet 1993, 4:311-313.
15. Bonne G, Carrier L, Komajda M, Schwartz K: The COX8 gene is not the disease gene of the CMH 4 locus in familial hypertrophic cardiomyopathy. J Med Genet 1995, 32:670-671.
16. Gautel M, Zutfardi O, Freiburg A, Labeit S: Phosphorylation switches specific for the cardiac isoform of myosin binding protein C: a modulator of cardiac contraction? EMBO J 1995, 14:1952-1960. Cloning and characterization of the cardiac isoform of the MyBP-C gene.
17. Nakajima-Taniguichi C, Matsui H, Eguchi N, Nagata S, Kishimoto T, Yamauchi-Takihara K: A novel deletion mutation in the β-myosin heavy chain gene found in Japanese patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 1995, 27:2607-2612.
18. Marian AJ, Yu QT, Mares A, Hill R, Roberts R, Perryman MB: Detection of a new mutation in the β-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. J Clin Invest 1992, 90:2156-2165.
19. Nishi H, Kimura A, Harada H, Koga Y, Adachi K, Matsuyama K, Koyanagi T, Yasunaga S, Imaizumi T, Toshima H, Sasazuki T: A myosin missense mutation, not a null allele. causes familial hypertrophic cardiomyopathy. Circulation 1995, 91:2911-2915.
20. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H, et al.: Prognostic implications of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994, 93:280-285.
21. Fananapazir L, Epstein ND: Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical β-myosin heavy chain gene mutations. Circulation 1994, 89:22-32.
22. Lankford EB, Epstein ND, Fananapazir L, Sweeney HL: Abnormal contractile properties of muscle fibers expressing β-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 1995, 95:1409-1414. The first demonstration of contractile deficits associated with myosin heavy chain mutations in FHCM.
23. Marian AJ, Yu QT, Workman R, Greve G, Roberts R: Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993, 342:1085-1086.
24. Lechin M, Quinones MA, Omran A, Hill R, Yu Q-T, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ: Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995, 92:1808-1812.
25. Yoneya K, Okamoto H, Machida M, Onozuka H, Noguchi M, Mikami T, Kawaguchi H, Murakami M, Uede T, Kitabake A: Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1995, 130:1089-1093.
26. Michels VV, Moll PP, Miller FA, Fauk AJ, Chu JS, Driscoll DJ, Burnett JC, Rodenheffer RJ, Chesebro JH, Tazelaar HD: The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992, 326:77-82.
27. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, Boudoulas H, Basson CT, Baker III PB, Cody RJ, Fishman MC, et al.: A gene defect that causes conduction system desease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nat Genet 1994, 7:546-551. The first disease locus found in FDCM.
28. Olson TM, Keating MT: Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest 1996, 97:528-532. Identification of a FDCM disease locus in a family with dilated cardiomyopathy associated with sinus node dysfunction.
29. Krajinovic M, Pinamonti B, Sinagra G, Vatta M, Severini GM, Milasin J, Falaschi A, Camerini F, Giacca M, Mestroni L, and the Heart Muscle Disease Study Group: Linkage of familial dilated cardiomyopathy to chromosome 9. Am J Human Genet 1995, 57:846-852. Identification of a FDCM disease locus in a large six-generation kindred and in two smaller ones. Several candidates genes map to this region.
30. Durand JB, Bachinski LL, Bieling LC, Czernuszewicz GZ, Abchee AB, Yu QT, Tapscott T, Hill R, Ifegwu J, Marian AJ, et al.: Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation 1995, 92:3387-3389. Identification of a FDCM disease locus in a family of 46 members spanning four generations. The locus is rich in candidate genes.
31. Alpert NR, Gordon MS: Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 1962, 202:940-946.
32. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD: Troponin T isoform expression in humans: a comparison among normal and falling adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991, 69:1226-1233.
33. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD: Troponin T isoform expression in normal and failing human left ventricle: a correlation with myofibrillar ATPase activity. Basic Res Cardiol 1992, 87(suppl 1):117-127.
34. Mesnard L, Samson E, Espinasse I, Durand J, Neveux JY, Mercadier JJ: Molecular cloning and developmental expression in human cardiac troponin T. FEBS Lett 1993, 328:139-144.
35. Townsend PJ, Farza H, MasGeoch C, Spurr NK, Wade R, Gahlman R, Yacoub MH, Barton PJ: Human cardiac troponin T: identification of fetal isoforms and assignment of the TNNT2 locus to chromosome 1q. Genomics 1994, 21:311-316.
36. Anderson PAW, Greig A, Mark TM, Malouf MM, Oakley AE, Ungerleider RM, Allen PD, Kay BK: Molecular basis of human cardiac troponin T isoform expressed in developing, adult, and failing heart Circ Res 1995, 76:681-686.
37. Mesnard L, Logeart D, Taviaux S, Diriong S, Mercadier JJ, Samson F: Human cardiac troponin T: cloning and expression of new isoforms in the normal and railing heart. Circ Res 1995, 76:687-692.
38. Townsend PJ, Barton PJR, Yacoub MH, Farza H: Molecular cloning of human cardiac troponin T isoforms: expression in developing and failing heart J Mol Cell Cardiol 1995, 27:2223-2236.
39. Gulati J, Babu A, Nikolic SD, Starc V, Siri F: Shifts in contractile regulatory protein subunits troponin T and troponin I in cardiac hypertrophy. Biochem Biophys Res Commun 1994, 202:384-390.
40. Solaro RJ, Van Eyck J: Altered interactions among thin filament proteins modulate cardiac function. J Mol Cell Cardiol 1996, 28:217-230. Current perception of the complex allosteric-cooperative process of the transition of cardiac muscle myofilament activity from the diastolic to the systolic state.
41. Hart G: Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994, 28:933-946.
42. Beuckelmann DJ, Näbauer M, Erdmann E: Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992, 85:1046-1055.
43. Rossner KL: Calcium current in congestive heart failure of hamster cardiomyopathy. Am J Physiol 199, 260:H1179-H1186.
44. 2+ exchange current is increased in ventricular myocytes of Syrian hamsters (Bio 14.6) with cardiac failure. This increase, which appears related to the decreased SR function, may be responsible, at least in part, for increased action potential duration during cardiac failure.
45. Thuringer D, Coulombe A, Deroubaix E, Coraboeuf E, Mercadier JJ: Depressed transient outward current density in ventricular myocytes from cardiomyopathic syrian hamsters of different ages. J Mol Cell Cardiol 1996, 28:387-401.
46. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993, 73:379-385.
47. 2+ exchanger mRNA and protein. This may constitute an important adaptive mechanism to compensate for decreased SR function during cardiac failure.
48. Arai M, Matsui H, Penasamy M: Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 1994, 74:555-564.
49. Wankerl M, Schwartz K: Calcium transport proteins in the nonfailing and failing heart: gene expression and function. J Mol Med 1995, 73:487-496.
50. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 1995, 77:759-767.
51. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994, 75:434-442.
52. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson P, Harding SE: Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995, 92:2540-2549.
53. Hasenfuss G, Mulieri LA, Leavitt BJ, Allen PD, Haeberle JR, Alpert NR: Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ Res 1992, 70:1225-1232.
54. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990, 85:305-309.
55. 2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 1994, 90:653-657.
56. 2+-ATPase activity from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995, 92:3220-3228.
57. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR: Selective gene expression in falling human heart: quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation 1991, 83:1866-1872.
58. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M: Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993, 72:463-469.
59. Böhm M, Reiger B, Schwinger RHG, Erdmann E: cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 1994, 28:1713-1719.
60. Danielsen W, von der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Döring V, Kalmar P: Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 1989, 14:171-173.
61. Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR: Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest 1995, 95:888-894. The first study investigating in failing human ventricles the relative concentrations of mRNAs coding for the ryanodine receptor and the inositol 1,4,5-triphosphate receptor (IP3R). The accumulation of IP3R transcripts while ryanodine receptor transcripts decrease suggests the recruitment of a inositol phosphate-sensitive calcium pool for myofibrillar activation during end-stage heart failure.
62. Bristow MR, Feldman AM: Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. Basic Res Cardiol 1992, 87(suppl I): 15-35.
63. Brodde OE, Michel MC, Zerkowski HR: Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res 1995, 30:570-584.
64. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM: Reduced β1-receptor subtype messenger RNA abundance in the falling human heart J Clin Invest 1993, 92:2737-2745.
65. Ungerer M, Böhm M, Elce JS, Erdman E, Lohse MJ: Altered expression of β-adrenergic receptor kinase and β-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
66. Böhm M: Alterations of beta-adrenoceptor-G protein-regulated adenylyl cyclase in heart failure. Mol Cell Biochem 1995, 147:147-160.
67. Yamamoto J, Ohyanagi M, Monta M, Iwasaki T: β-adrenoceptor-G protein-adenylate cyclase complex in rat hearts with ischemic heart failure produced by coronary artery Ilgation. J Mol Cell Cardiol 1994, 26:617-626.
68. Taussig R, Gilman AG: Mammalian membrane-bound adenylyl cyclases. J Biol Chem 1995, 270:1-4.
69. Ishikawa Y, Sorota S, Kiuchi K, Shannon RP, Komamura K, Katsushika S, Vatner DE, Vatner SF, Homcy CJ: Downregulation of adenylyl cyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 1994, 93:2224-222. The first study investigating the mRNA concentrations of the two main cardiac adenylyl cyclase isoforms (types V and VI) in a model of heart failure. Decreased concentrations of the two mRNA isoforms occur in parallel with decreased basal and forskolin-stimulated adenylyl cyclase activities.
70. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homey CJ, Vatner SF, Vatner DE: Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 1993, 91:907-914.
71. Vatner DE, Sato N, Kiuchi K, Shannon RP, Vatner SF: Decrease in myocardial ryanodine receptors and altered excitation-contraction coupling early in the development of heart failure. Circulation 1994, 90:1423-1430.
72. Bing OHL: Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994, 26:943-948.
73. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M: Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994, 75:426-433.
74. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL: Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994, 94:1621-1628.
75. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P: Stretch-induced programmed myocyte cell death. J Clin Invest 1995, 96:2247-2259. An important study indicating that overstretching rat papillary muscles is associated with a marked increase in apoptopic myocyte cell death and, to a lesser extent, with increased apoptotic nonmyocyte cell death. If operative during heart failure, this mechanism could play an important role in myocardial remodeling during cardiac failure.